India GlycolsBOM:500201 +4.80%66 EBITDA Margin % is 18.45% as of Mar. 2026, which is 44% above its 10-year median of 12.85. GuruFocus rates BOM:500201 with a GF Score™ of 66/100 and a GF Value™ of ₹752.37 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,579 Chemicals companies, India Glycols ranks better than 73.46% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. India Glycols's EBITDA for the
three
months ended in Mar. 2026 was ₹1,801 Mil. India Glycols's Revenue for the
three
months ended in Mar. 2026 was ₹9,764 Mil. Therefore, India Glycols's EBITDA margin for the quarter that ended in Mar. 2026 was 18.45%.
India Glycols (BOM:500201) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
India Glycols EBITDA Margin % Related Terms
India Glycols EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for India Glycols's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, India Glycols's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
India Glycols EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, India Glycols's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where India Glycols's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
India Glycols (BOM:500201) has a EBITDA Margin % of 18.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on India Glycols and its competitors. This is 44% above median its historical median of 12.85. Over the past decade, India Glycols' EBITDA Margin % has ranged from 8.62 to 18.03. According to the industry distribution chart, India Glycols ranks #419 out of 1579 companies in the Chemicals industry, placing it in the top 26.5%.
Is India Glycols' EBITDA Margin % too high?
India Glycols' current EBITDA Margin % of 18.45% is 44% above median its 10-year median of 12.85. Over the past 10 years, this metric has ranged from a low of 8.62 to a high of 18.03. The Chemicals industry median EBITDA Margin % is 9.63. India Glycols' value of 18.45% is 91.6% above this industry median. Based on the distribution chart, India Glycols ranks #419 out of 1579 companies in the Chemicals industry, which is above the industry midpoint. Overall, India Glycols has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does India Glycols' EBITDA Margin % compare to DOW?
According to the Chemicals industry distribution chart, India Glycols ranks #419 out of 1579 companies for EBITDA Margin %. This puts India Glycols in the upper half of its industry. The industry median EBITDA Margin % is 9.63. India Glycols' value of 18.45% is 91.6% above this benchmark. Historically, India Glycols' own EBITDA Margin % has ranged from 8.62 to 18.03 over the past decade. While the company's 10-year median is 12.85 vs. the industry median of 9.63, India Glycols has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.63, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. India Glycols's current EBITDA Margin % of 18.45% is 91.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on India Glycols and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. India Glycols's current EBITDA Margin % is 18.45%, which is 44% above median its own 10-year median of 12.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is India Glycols stock overvalued right now?
Based on GuruFocus' analysis, India Glycols (BOM:500201) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹752.37, compared to a current price of ₹1,076.15 — trading 43% above its estimated fair value. The current EBITDA Margin % is 18.45%, which is 44% above median its 10-year median of 12.85 and 91.6% above the Chemicals industry median of 9.63. India Glycols' overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For India Glycols (BOM:500201), the current EBITDA Margin % is 18.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is India Glycols (BOM:500201) Overvalued in 2026?
Based on GuruFocus' analysis, India Glycols stock appears to be overvalued.
The current stock price of ₹1,076.15 is trading 43% above its estimated GF Value™ of ₹752.37.
GuruFocus considers India Glycols to be Significantly Overvalued.
Key valuation signals for BOM:500201:
EBITDA Margin %: 18.45% (44% above median its 10-year median of 12.85)
GF Value™: ₹752.37 vs. price of ₹1,076.15 (43% above fair value)
Industry Position: 91.6% above the Chemicals median (#419 of 1579)
No single metric tells the full story. See the BOM:500201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
India Glycols Ltd is engaged in the manufacture of Bio-Based Specialities and Performance Chemicals, such as green technology-based bulk products, natural gums, and industrial gases; Potable Spirits, and Ennature Biopharma. The company operates through industries of Pharma & Healthcare, Oil & Gas, Textile, Food Ingredients, Automotive, Packaging, Personal Care, Potable Spirits, and Industrial and Manufacturing. Its operating segments are Bio-based Specialities and Performance Chemicals comprise Glycols, Specialty Chemicals, Natural Gum & other related goods, etc; Potable Spirits comprises the manufacture and sale of Ethyl Alcohol (Potable); Ennature Biopharma comprises the manufacture and sale of Nutraceutical Products; and Bio-fuel comprises Ethanol, DDGS & DWGS.
66GF Score
Get the complete analysis for BOM:500201
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500201 has been successfully added to your 
